Waikato Business News RECAP 2019
A wrap up of the year’s success, innovation and growth stories in the Waikato business community
A wrap up of the year’s success, innovation and growth stories in the Waikato business community
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
WAIKATO FIRM POISED<br />
FOR MEDICINAL CANNABIS WAVE<br />
<strong>Waikato</strong> Innovation Park-based medicinal cannabis firm<br />
Cannasouth made headlines when it listed on the New<br />
Zealand Stock Exchange in June.<br />
THE STORY THEN:<br />
Aug 1 - <strong>Waikato</strong> firm Cannasouth has been<br />
building a big surfboard. That’s because it’s got<br />
a big wave to catch.<br />
The wave is medicinal cannabis and the analogy<br />
comes from the company’s chief executive,<br />
Mark Lucas.<br />
Cannasouth recently listed on the NZX, the first<br />
company to do so in two years, and the first<br />
medicinal cannabis company to take the step.<br />
It recently appointed a new product development<br />
manager, scientist David Gill, and is<br />
well underway with developing cannabinoid<br />
products using its labs at Innovation Park and<br />
Hamilton East’s secure growing facility.<br />
Timing is everything, and the introduction of the<br />
Misuse of Drugs (Medicinal Cannabis) Amendment<br />
Act last year has been followed by the<br />
release for feedback in July of a discussion document<br />
aimed at setting up a regulatory scheme,<br />
with Cannasouth set to be among those submitting<br />
before the August 7 cutoff.<br />
“It’s like surfing,” Lucas says. “The big wave<br />
surfers get on the weather maps and they know<br />
when there’s a storm out there. It might be a<br />
week before the waves arrive. They fly to to get<br />
those waves. But to surf big waves you need a<br />
big board.<br />
“We were out there and we realised, well this<br />
wave’s pretty big; to compete, or to get on the<br />
wave, we need to build a big board and that’s<br />
raising capital.”<br />
The listing in June at 50c a share was oversubscribed<br />
and saw the company raise $10 million.<br />
Lucas is at pains to stress they are in for the long<br />
haul, after being frustrated by some negative<br />
media commentary around the listing, which he<br />
says implied the cofounders and early investors<br />
would look to quickly sell their shares.<br />
The price has since steadied around 37c at time<br />
of writing, and Lucas says the share price may<br />
have been affected by the commentary, as well<br />
as potential confusion around the medicinal cannabis<br />
scheme and the adult recreational debate.<br />
Cannasouth has been heavily involved in<br />
research, developing its own IP, but Lucas and<br />
chief operating officer Nic Foreman recognise<br />
the commercial realities as well.<br />
“There’s going to be a lot of competition but the<br />
space itself is also looking like it’s going to be<br />
rather large.”<br />
The medicinal potential of cannabinoids has<br />
been touted as potentially helping with a range<br />
of conditions from anxiety, through inflammation<br />
to epilepsy and Crohn’s Disease among others.<br />
RESEARCH HAS BEEN A FOCUS FOR CHIEF EXECUTIVE<br />
MARK LUCAS AND THE CANNASOUTH TEAM.<br />
Exporting is part of Cannasouth’s plan and it<br />
intends to take a broad approach in the market;<br />
while its focus has been on developing medicines,<br />
there is also potential in neutraceuticals<br />
potentially including fortified waters and sports<br />
recovery drinks.<br />
The “holy grail” would be to come up with<br />
their own medicine that can treat a specific<br />
condition and be “novel and unique”.<br />
THE STORY SINCE:<br />
In August, Cannasouth announced a longterm<br />
strategic joint venture (JV) with Aaron<br />
Craig and his family (Craig Family Interests) to<br />
construct and develop a world-class cannabis<br />
cultivation facility in <strong>Waikato</strong>.<br />
The JV will construct and operate a medicinal<br />
cannabis and hemp cultivation and production<br />
facility, which will service and supply Cannasouth’s<br />
production requirements. It is expected<br />
to be fully operational by mid-2020.<br />
Also in August, Cannasouth harvested its first<br />
crop of medicinal research cannabis from its<br />
purpose-built growing facility in Hamilton.<br />
By September, the total number of individual<br />
registered investors in Cannasouth passed<br />
2000, up from the approximately 1450 following<br />
its listing in June. At the start of October,<br />
Cannasouth entered into an agreement to<br />
acquire a 60 percent shareholding in Hawke’s<br />
Bay-based Midwest Pharmaceutics NZ Limited<br />
for a purchase price of $1.32 million. The<br />
acquisition will add significantly to the suite of<br />
licences that can be utilised by the Cannasouth<br />
group.<br />
In early December, Cannasouth shares were<br />
trading around 63c.<br />
GET THE WAIKATO’S AWARD WINNING ELECTRICAL EXPERTS ON THE JOB TODAY<br />
MASTER ELECTRICIANS<br />
EXCELLENCE AWARDS<br />
<strong>2019</strong><br />
SILVER FOR PROJECT<br />
“HILTON” $1-5 MILLION<br />
RAISING THE BARR IN ELECTRICAL SERVICE<br />
WHERE QUALITY & SERVICE COUNT<br />
For your next Electrical Project talk to the award<br />
winning team at RichmondBarr Electrical<br />
Commercial Electric Projects<br />
Electrical Service<br />
Heavy Industrial<br />
Communication & Automation<br />
Design & Bulk Projects<br />
Commercial Kitchens<br />
MORE THAN JUST ELECTRICIANS<br />
Call us 24 hours 07 847 9845<br />
service@richmondbarr.co.nz<br />
www.richmondbarr.co.nz<br />
203710AA<br />
8 WAIKATO BUSINESS NEWS - <strong>RECAP</strong> December <strong>2019</strong>